| Literature DB >> 21187478 |
Ulisse Cucchi1, Laura M Gianellini, Anna De Ponti, Francesco Sola, Rachele Alzani, Veronica Patton, Alice Pezzoni, Sonia Troiani, Maria B Saccardo, Simona Rizzi, Maria L Giorgini, Paolo Cappella, Italo Beria, Barbara Valsasina.
Abstract
Polo-like kinase 1 (PLK1) is the master regulator of mitosis and a target for anticancer therapy. To develop a marker of PLK1 activity in cells and tumour tissues, this study focused on translational controlled tumour protein (TCTP) and identified serine 46 as a site phosphorylated by PLK1 in vitro. Using an antibody raised against phospho-TCTP-Ser46, it was demonstrated that phosphorylation at this site correlates with PLK1 level and kinase activity in cells. Moreover, PLK1 depletion by siRNA or inactivation by specific inhibitors caused a correspondent decrease in phospho-TCTP-Ser46 signal validating this site as a direct marker of PLK1. Using this marker, the study characterized PLK1 inhibitors in cells by setting up a high-content assay and finally immunohistochemical assay suitable for following inhibitor activity in preclinical tumour models and possibly in clinical studies was developed.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21187478
Source DB: PubMed Journal: Anticancer Res ISSN: 0250-7005 Impact factor: 2.480